Naslov
Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co- transporter 2 inhibitors

Autori
Lakušić, Nenad ; Merkaš, Ivana Sopek ; Slišković, Ana Marija ; Cerovec, Dora

Izvornik
World Journal of Cardiology (1949-8462) 14 (2022), 10; 561-564

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
Sodium-glucose co-transporter 2 inhibitors, Euglycemic diabetic ketoacidosis, Chronic heart failure

Sažetak
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an insulin-independent class of oral antihyperglycemic medication and from recently established therapy in chronic heart failure patients. A rare, but potentially life-threatening complication of SGLT2 inhibitor use is euglycemic diabetic ketoacidosis. We described a case of a middle-aged male patient with type 2 diabetes who developed metabolic ketoacidosis after a few days of empagliflozin administration. SGLT2 inhibitor related ketoacidosis presents with euglycemia or only modestly elevated glucose blood concentrations, which causes delayed detection and treatment of ketoacidosis. There are multiple possible risk factors and mechanism that might contribute to the pathogenesis of ketoacidosis. It is implied that SGLT2 inhibitor use and prescription by non-diabetologists (cardiologists, nephrologists, family physicians, etc.) will continue to grow in the future. It is important to inform the general cardiac public about this rare but serious side effect of SGLT2 inhibitors.

Izvorni jezik
Engleski

POVEZANOST RADA